 |
Anticancer therapeutics / edited by Sotiris Missailidis. — Oxford : Wiley-Blackwell, 2008. – (64.86/A629) |
Contents
Contents
Forward
Acknowledgements
List of contributors
SECTION I: Development of Anticancer Therapeutics
1 Exploring the Potential of Natural Products in Cancer Treatment
1.1 Introduction
1.2 Sources
1.3 Different Approaches to the Search for Bioactive Natural Products
1.4 Methodologies of Lead Compound or New Drug Identification
1.5 Chemoprevention - A New Area for Natural Product Research
1.6 Concluding Remarks
2 Combinatorial Approaches to Anticancer Drug Design
2.1 Introduction
2.2 Combinatorial Approaches for Small Molecule Drug Design
2.3 Display Technologies
2.4 Aptamer Selection
2.5 Conclusions
3 Rational Approaches to Anticancer Drug Design/in silico Drug Development
3.1 Introduction
3.2 Approaches to the Drug Discovery Process in Anticancer Research
3.3 Ligand-based Examples
3.4 Structure-based Examples
3.5 Conclusions
SECTION II: Anticancer Therapeutics
4 Introduction to Anticancer Therapeutics
4.1 Problems in cancer
4.2 Cancer treatments
4.3 Classification of chemotherapy drugs
5 Platinum Drugs
5.1 Cisplatin
5.2 Lipoplatin
5.3 Carboplatin
5.4 Oxaliplatin
5.5 Lipoxal
5.6 New Platinum Compounds
5.7 Cisplatin Resistance and Chemotherapy
6 Antimicrotubule Agents
6.1 Taxanes
6.2 Vinca Alkaloids
6.3 Mechanisms of Resistance to Antimicrotubule Agents
7 Antimetabolites in Cancer Therapy
7.1 Introduction
7.2 Folate Antagonists
7.3 Pyrimidine Antagonists
7.4 Purine Antagonists
7.5 Summary
8 Antitumour Antibiotics
8.1 Introduction
8.2 Actinomycin
8.3 Mitomycin C
8.4 Bleomycin
8.5 Anthracyclines
8.6 Trabectedin (Ecteinascidin， ET-743)
8.7 Camptothecins
8.8 Podophyllotoxins
9 Alkylating Agents
9.1 Introduction
9.2 Nitrogen Mustards
9.3 Methylmelamines and Ethylenimines
9.4 Methythydrazine Derivatives
9.5 Alkylsulfonates
9.6 Nitrosoureas
9.7 Triazenes
10 Hormone Therapies
10.1 Introduction
10.2 Oestrogen Receptor Targeted Therapeutics
10.3 Progesterone-Targeted Therapy
10.4 Neuroendocrine Tumours
11 Photodynamic Therapy of Cancer
11.1 Introduction
11.2 Photosensitizers
11.3 Outlook
11.4 Acknowledgement
12 Target-directed Drug Discovery
12.1 Introduction
12.2 Tyrosine Kinases - Role and Significance in Cancer
12.3 Targeted Therapy for the Treatment of Non-small Ceil Lung Cancer (NSCLC)
12.4 Targeted Therapy for the Treatment of Chronic Myeloid Leukaemia
12.5 Targeted Therapy for the Treatment of Breast Cancer
12.6 Angiogenesis
12.7 Targeting Cell Cycling
12.8 Targeting Apoptosis
12.9 Targeting mTOR
12.10 The Future of Molecularly Targeted Therapy
13 Tumour Hypoxia: Malignant Mediator
13.1 Introduction
13.2 Hypoxia Inducible Factor-1 and Hypoxia
13.3 HIF-1α Post-translational Changes
13.4 How Genetics Can Modify HIF
13.5 How Tumours Overcome Hypoxia with HIF-1
13.6 HIF-1 Therapeutics
13.7 Conclusion
14 Resistance to Chemotherapy Drugs
14.1 Introduction
14.2 What are the Factors Limiting the Efficacy of Cancer Chemotherapy Treatment?
14.3 A Classification of the Important Chemotherapy Resistance Mechanisms
14.4 Illustrative Mechanisms of Pharmacokinetic Resistance
14.5 Illustrative Mechanisms of Pharmacodynamic Resistance
14.6 Conclusion
15 Cancer Immunotherapy
15.1 The Molecular Basis of Cancer Immunotherapy and Gene Immunotherapy of Cancer
15.2 Recombinant Monoclonal Antibodies
15.3 Cell Immunotherapy
15.4 Cancer Vaccines
16 Gene Therapy
16.1 The Concept of Gene Therapy
16.2 Steps for Successful Gene Therapy
16.3 Retroviruses in Cancer Gene Therapy
16.4 Adenoviruses in Cancer Gene Therapy
16.5 Gene Therapy of Cancer
16.6 Cancer Immunotherapy with Cytokine Genes
16.7 IL-12 in Cancer Immunotherapy
16.8 Viruses able to Kill Cancer Cells
17 Antisense Agents
17.1 Introduction
17.2 Traditional Antisense Oligonucleotides (ASOs)
17.3 Ribozymes and DNAzymes
17.4 RNA Interference and siRNAs
17.5 Shortcomings of Antisense Therapeutics
17.6 Antisense Agents in Clinical Trials
17.7 Concluding Remarks
18 Aptamers as Anticancer Agents
18.1 Introduction
18.2 Aptamers in Cancer
18.3 Final comments
SECTION III: Other Aspects in Anticancer Therapeutic Development
19 Treatment of Cancer in Conjunction with Other Agents
19.1 Introduction
19.2 Non-steroidal Anti-inflammatory Drugs
19.3 Angiotensin-converting Enzyme (ACE) Inhibitors and Angiotensin Receptor Blockade
19.4 Partners in Crime - Dealing with Co-infections
19.5 Discussion
20 Clinical Trials in Oncology
20.1 Clinical Trials
20.2 Early-Phase (Phase I and Phase I1) Clinical Trials in Oncotogy
20.3 Confirmatory (Phase III) Trials in Oncology
20.4 Further Issues in Clinical Trials in Oncology
21 Representative Cancers， Treatment and Market
21.1 Lung Cancer
21.2 Breast Cancer
21.3 Prostate Cancer
21.4 Colorectal Cancer
21.5 Ovarian Cancer
21.6 Pancreatic Cancer
21.7 Gastric Cancer
21.8 Combination Chemotherapy
21.9 The Pharmaceutical World of Anticancer Drugs
22 Future Trends in Cancer Therapeutics
22.1 Introduction
22.2 Personalized Medicines
22.3 Delivery Systems
22.4 Closing Remarks
Index
